Early Hydroxychloroquine Slows Cutaneous Lupus Progression A prospective study of patients with limited cutaneous lupus erythematosus (CLE) shows that early introduction of hydroxychloroquine (HCQ) may prevent progression to systemic lupus erythematosus (SLE).… https://t.co/evsvf2GQiL https://t.co/J0Zl35FEHz

Full read review of Hydryoxychloroquine -its pharmacology, MOA (eg, blocking TLR 7 & 9), Dz specific efficacy and adverse effects https://t.co/N7XVbfnsfi https://t.co/yjKwcfugOJ

Bubble Trouble - When Bullous Lupus Bursts onto the SLE Scene Presentation by Dr. Alana Haussmann at the Rheumatology Winter Clinical Symposia - Feb 2025 https://t.co/N4u4AUbdqH https://t.co/PotKfpOkH7

Available the first time: https://t.co/4UQlqwujiR 2025 On Demand! On Demand gives you access to all lectures, Q & A panels, and STEP talks, and all speaker slides and handouts — all packed with insights you won’t find anywhere else. Non-CME, practical, and finally here.… https://t.co/MHFUWb3az1 https://t.co/cqzZG40Xp5

An Unusual Consult for Myopathy Presentation by Dr. Kelsey Lemmen, at the Rheumatology Winter Clinical Symposia - Feb 2025 https://t.co/DYlzee6qcs https://t.co/nUxTC9roF9

A Review of Relapsing Polychondritis A current review in the Journal of Thoracic Disease on relapsing polychondritis (RP), suggests that while this rare disorder may have an uncertain pathogenesis, its diagnosis and therapeutical management has improved.… https://t.co/keacvqjlU7 https://t.co/TkYwNnYtxF

Crohn’s Microbiome may Predispose to Axial Spondyloarthritis Researchers at Weill Cornell Medicine found that people with Crohn’s disease and related joint inflammation have distinct gut bacteria, with Mediterraneibacter gnavus as a potential biomarker. https://t.co/SI03wAJ3UU https://t.co/dlt3VxBDLw

CDC: More women (25.4%) than men (23.2%) had chronic pain in last 3 mos, Esp in large central metropolitan areas(22% vs 19%, F>M). For both recent chronic pain increased with decreasing urbanicity. https://t.co/rDsCQWvAae https://t.co/mhczpWFsdw

Neuropsychiatric Lupus: More than just a headache Presentation by Dr. Daniel Carlson, at the Rheumatology Winter Clinical Symposia - Feb 2025 https://t.co/v0da4UNFNV https://t.co/BhBKOgak4W

Normalizing Serologies Enhances Remission in SLE Analysis of five phase III belimumab (BEL) trials reveals that normalizing serologies affords protection against severe and renal SLE flares, supporting the concept of treat-to-target to minimize risk in SLE.… https://t.co/eW9EUyvts7 https://t.co/OdM0WkLtjd